cloudfront

Report Detail

Pharma & Healthcare Global (United States, European Union and China) Antidiabetic SGLT-2 Inhibitor Market Research Report 2019-2025

  • RnM3321530
  • |
  • 17 April, 2019
  • |
  • Global
  • |
  • 112 pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Global (United States, European Union and China) Antidiabetic SGLT-2 Inhibitor Market Research Report 2019-2025

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Canagliflozin
      • 1.3.3 Empagliflozin
      • 1.3.4 Dapagliflozin
      • 1.3.5 Other
    • 1.4 Market Segment by Application
      • 1.4.1 Global Antidiabetic SGLT-2 Inhibitor Market Share by Application (2019-2025)
      • 1.4.2 Hospitals
      • 1.4.3 Clinics
      • 1.4.4 Other
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Antidiabetic SGLT-2 Inhibitor Market Size
      • 2.1.1 Global Antidiabetic SGLT-2 Inhibitor Revenue 2014-2025
      • 2.1.2 Global Antidiabetic SGLT-2 Inhibitor Sales 2014-2025
    • 2.2 Antidiabetic SGLT-2 Inhibitor Growth Rate by Regions
      • 2.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Regions 2014-2019
      • 2.2.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Antidiabetic SGLT-2 Inhibitor Sales by Manufacturers
      • 3.1.1 Antidiabetic SGLT-2 Inhibitor Sales by Manufacturers 2014-2019
      • 3.1.2 Antidiabetic SGLT-2 Inhibitor Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Antidiabetic SGLT-2 Inhibitor Revenue by Manufacturers (2014-2019)
      • 3.2.2 Antidiabetic SGLT-2 Inhibitor Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Antidiabetic SGLT-2 Inhibitor Market Concentration Ratio (CR5 and HHI)
    • 3.3 Antidiabetic SGLT-2 Inhibitor Price by Manufacturers
    • 3.4 Key Manufacturers Antidiabetic SGLT-2 Inhibitor Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Antidiabetic SGLT-2 Inhibitor Market
    • 3.6 Key Manufacturers Antidiabetic SGLT-2 Inhibitor Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Canagliflozin Sales and Revenue (2014-2019)
      • 4.1.2 Empagliflozin Sales and Revenue (2014-2019)
      • 4.1.3 Dapagliflozin Sales and Revenue (2014-2019)
      • 4.1.4 Other Sales and Revenue (2014-2019)
    • 4.2 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type
    • 4.3 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type
    • 4.4 Antidiabetic SGLT-2 Inhibitor Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Application

    6 United States

    • 6.1 United States Antidiabetic SGLT-2 Inhibitor Breakdown Data by Company
    • 6.2 United States Antidiabetic SGLT-2 Inhibitor Breakdown Data by Type
    • 6.3 United States Antidiabetic SGLT-2 Inhibitor Breakdown Data by Application

    7 European Union

    • 7.1 European Union Antidiabetic SGLT-2 Inhibitor Breakdown Data by Company
    • 7.2 European Union Antidiabetic SGLT-2 Inhibitor Breakdown Data by Type
    • 7.3 European Union Antidiabetic SGLT-2 Inhibitor Breakdown Data by Application

    8 China

    • 8.1 China Antidiabetic SGLT-2 Inhibitor Breakdown Data by Company
    • 8.2 China Antidiabetic SGLT-2 Inhibitor Breakdown Data by Type
    • 8.3 China Antidiabetic SGLT-2 Inhibitor Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Antidiabetic SGLT-2 Inhibitor Breakdown Data by Company
    • 9.2 Rest of World Antidiabetic SGLT-2 Inhibitor Breakdown Data by Type
    • 9.3 Rest of World Antidiabetic SGLT-2 Inhibitor Breakdown Data by Application
    • 9.4 Rest of World Antidiabetic SGLT-2 Inhibitor Breakdown Data by Countries
      • 9.4.1 Rest of World Antidiabetic SGLT-2 Inhibitor Sales by Countries
      • 9.4.2 Rest of World Antidiabetic SGLT-2 Inhibitor Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Pfizer
      • 10.1.1 Pfizer Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Antidiabetic SGLT-2 Inhibitor
      • 10.1.4 Antidiabetic SGLT-2 Inhibitor Product Introduction
      • 10.1.5 Pfizer Recent Development
    • 10.2 AstraZeneca
      • 10.2.1 AstraZeneca Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Antidiabetic SGLT-2 Inhibitor
      • 10.2.4 Antidiabetic SGLT-2 Inhibitor Product Introduction
      • 10.2.5 AstraZeneca Recent Development
    • 10.3 Johnson & Johnson
      • 10.3.1 Johnson & Johnson Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Antidiabetic SGLT-2 Inhibitor
      • 10.3.4 Antidiabetic SGLT-2 Inhibitor Product Introduction
      • 10.3.5 Johnson & Johnson Recent Development
    • 10.4 GlaxoSmithKline
      • 10.4.1 GlaxoSmithKline Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Antidiabetic SGLT-2 Inhibitor
      • 10.4.4 Antidiabetic SGLT-2 Inhibitor Product Introduction
      • 10.4.5 GlaxoSmithKline Recent Development
    • 10.5 Merck & Co
      • 10.5.1 Merck & Co Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Antidiabetic SGLT-2 Inhibitor
      • 10.5.4 Antidiabetic SGLT-2 Inhibitor Product Introduction
      • 10.5.5 Merck & Co Recent Development
    • 10.6 Eli Lilly
      • 10.6.1 Eli Lilly Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Antidiabetic SGLT-2 Inhibitor
      • 10.6.4 Antidiabetic SGLT-2 Inhibitor Product Introduction
      • 10.6.5 Eli Lilly Recent Development
    • 10.7 Sanofi
      • 10.7.1 Sanofi Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Antidiabetic SGLT-2 Inhibitor
      • 10.7.4 Antidiabetic SGLT-2 Inhibitor Product Introduction
      • 10.7.5 Sanofi Recent Development
    • 10.8 Takeda Pharmaceuticals
      • 10.8.1 Takeda Pharmaceuticals Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Antidiabetic SGLT-2 Inhibitor
      • 10.8.4 Antidiabetic SGLT-2 Inhibitor Product Introduction
      • 10.8.5 Takeda Pharmaceuticals Recent Development
    • 10.9 Novo Nordisk
      • 10.9.1 Novo Nordisk Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Antidiabetic SGLT-2 Inhibitor
      • 10.9.4 Antidiabetic SGLT-2 Inhibitor Product Introduction
      • 10.9.5 Novo Nordisk Recent Development
    • 10.10 Servier Laboratories
      • 10.10.1 Servier Laboratories Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Antidiabetic SGLT-2 Inhibitor
      • 10.10.4 Antidiabetic SGLT-2 Inhibitor Product Introduction
      • 10.10.5 Servier Laboratories Recent Development
    • 10.11 Boehringer Ingelheim
    • 10.12 Bristol-Myers Squibb

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Antidiabetic SGLT-2 Inhibitor Sales Channels
      • 11.2.2 Antidiabetic SGLT-2 Inhibitor Distributors
    • 11.3 Antidiabetic SGLT-2 Inhibitor Customers

    12 Market Forecast

    • 12.1 Global Antidiabetic SGLT-2 Inhibitor Sales and Revenue Forecast 2019-2025
    • 12.2 Global Antidiabetic SGLT-2 Inhibitor Sales Forecast by Type
    • 12.3 Global Antidiabetic SGLT-2 Inhibitor Sales Forecast by Application
    • 12.4 Antidiabetic SGLT-2 Inhibitor Forecast by Regions
      • 12.4.1 Global Antidiabetic SGLT-2 Inhibitor Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Antidiabetic SGLT-2 Inhibitor Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Antidiabetic SGLT-2 Inhibitor is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Antidiabetic SGLT-2 Inhibitor.

      This report studies the global market size of Antidiabetic SGLT-2 Inhibitor, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Antidiabetic SGLT-2 Inhibitor sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Pfizer
      AstraZeneca
      Johnson & Johnson
      GlaxoSmithKline
      Merck & Co
      Eli Lilly
      Sanofi
      Takeda Pharmaceuticals
      Novo Nordisk
      Servier Laboratories
      Boehringer Ingelheim
      Bristol-Myers Squibb

      Market Segment by Product Type
      Canagliflozin
      Empagliflozin
      Dapagliflozin
      Other

      Market Segment by Application
      Hospitals
      Clinics
      Other

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Antidiabetic SGLT-2 Inhibitor status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Antidiabetic SGLT-2 Inhibitor manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Antidiabetic SGLT-2 Inhibitor are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025




      Summary:
      Get latest Market Research Reports on Antidiabetic SGLT-2 Inhibitor . Industry analysis & Market Report on Antidiabetic SGLT-2 Inhibitor is a syndicated market report, published as Global (United States, European Union and China) Antidiabetic SGLT-2 Inhibitor Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Antidiabetic SGLT-2 Inhibitor market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,280.00
      $4,920.00
      $6,560.00
      2,202.52
      3,303.78
      4,405.04
      3,018.26
      4,527.38
      6,036.51
      397,339.20
      596,008.80
      794,678.40
      217,507.95
      326,261.93
      435,015.90
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report